Global distribution of Helixate ecombinant coagulation Factor VIII will run through through 2017.



CSL Behring reached an agreement with Bayer HealthCare to continue the supply and distribution of a therapy for the treatment of hemophilia A. Bayer will provide Helixate® recombinant coagulation Factor VIII to CSL Behring through 2017.


Additionally, Bayer was granted a license to intellectual property related to recombinant FVIII. At the same time, the companies settled outstanding litigation relating to the supply of recombinant Factor VIII.








This site uses Akismet to reduce spam. Learn how your comment data is processed.